Sains Malaysiana 49(2)(2020): 237-248

http://dx.doi.org/10.17576/jsm-2020-4902-02

Impact of Nitric Oxide Synthase 2 Gene Variant on Risk of Anti-Tuberculosis Drug- Induced Liver Injury in the Malaysian Population

(Kesan Variasi Gen Nitrik Oksida Synthase 2 terhadap Risiko Kerosakan Hati Akibat Ubat Anti-Tuberkulosis dalam Populasi Malaysia)

VISHALA SIVAPALAN¹*, SHAMSUL MOHD ZAIN², SHENGNAN JIN³, SZE LING CHAN³, JIAJUN LIU⁴, ZAHURIN MOHAMED² & ROSMAWATI MOHAMED¹

¹Department of Medicine, University of Malaya, 50603 Kuala Lumpur, Federal Territory, Malaysia

²Department of Pharmacology, University of Malaya, 50603 Kuala Lumpur, Federal Territory, Malaysia

³Translational Laboratory in Genetic Medicine (TLGM), A*Star, 117609, Singapore

⁴Genome Institute of Singapore, A*Star, 60 Biopolis St., 138672, Singapore

Diserahkan: 4 Ogos 2019/Diterima: 5 Disember 2019

ABSTRACT

Liver injury is a great threat associated with anti-tuberculosis (anti-TB) medication. Genetic variations in genes encoding drug-metabolising enzymes further enhance this threat. We aimed to explore genetic contributions by evaluating the impact of single nucleotide polymorphisms (SNPs) within the anti-tuberculosis (AT) metabolism pathway genes and within their respective chromosomes on anti-tuberculosis drug- induced liver injury (AT-DILI). Patients (n= 90) were recruited and 170 SNPs were genotyped using Illumina array and validated using Sanger Sequencing. The well-studied N-acetyltransferase 2 (NAT2*6) rs1799930 and cytochrome P450 2E1 (CYP2E1) C1/C1 were not significantly associated with AT-DILI in our cohort but nitric oxide synthase (NOS2A) rs11080344-C was found to be significantly higher in the cases than the controls (OR 2.73, 95% CI 1.12-6.64, P= 0.027). Association studies on all other SNPs within the anti-tuberculosis metabolism pathway genes and within their respective chromosomes also found no significant report. Our study suggests that genetic variation in NOS2A could influence the occurrence of AT-DILI.

Keywords: Adverse effect; genetic variations; liver injury; nitric oxide; tuberculosis

ABSTRAK

Kerosakan hati adalah ancaman besar yang dikaitkan dengan pengambilan ubat-ubatan anti-tuberkulosis. Variasi genetik dalam gen yang mengekod enzim yang terlibat dalam metabolisme ubat meningkatkan ancaman tersebut. Tujuan kami adalah untuk mengkaji pengaruh genetik dengan menilai impak polimorfisme nukleotid tunggal (SNPs) di dalam gen-gen yang terlibat dalam laluan metabolisme ubat-ubatan anti-tb dan dalam kromosom masing-masing terhadap kecenderungan kerosakan hati akibat ubat anti-tuberkulosis (AT-DILI). Pesakit (n=90) direkrut dan 170 SNPs digenotip menggunakan tatasusunan Illumina dan disahkan menggunakan penjujukan Sanger. Gen N-asetiltransferase 2 (NAT2*6) rs1799930 dan sitokrom P450 2E1 (CYP2E1) C1/C1 yang dikaji secara meluas tidak mempunyai kaitan signifikan dengan AT-DILI dalam kohort kami tetapi nitrik oksida sintase (NOS2A) rs11080344-C didapati secara signifikannya lebih tinggi dalam subjek kes berbanding dengan subjek kawalan (OR 2.73, 95% CI 1.12-6.64, P= 0.027). Kajian SNPs lain yang terlibat di dalam gen dalam laluan matabolisme ubat-ubatan anti-tuberkulosis dan kromosom masing-masing juga tidak menunjukkan kaitan yang signifikan. Kajian kami mencadangkan bahawa variasi genetik di dalam NOS2A boleh mempengaruhi kejadian AT-DILI.

Kata kunci: Kerosakan hati; kesan buruk; nitrik oksida; tuberkulosis; variasi genetic

RUJUKAN

Azuma, J., Ohno, M., Kubota, R., Yokota, S., Nagai, T., Tsuyuguchi, K., Okuda, Y., Takashima, T., Kamimura, S., Fujio, Y. & Kawase, I. 2013. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy. European Journal of Clinical Pharmacology 69(5): 1091-1101.

Deng, L., Hoh, B.P., Lu, D., Saw, W.Y., Twee-Hee Ong, R., Kasturiratne, A., Janaka de Silva, H., Zilfalil, B.A., Kato, N., Wickremasinghe, A.R., Teo, Y.Y. & Xu, S. 2015. Dissecting the genetic structure and admixture of four geographical Malay populations. Scientific Reports 5: 14375.

Du, H., Chen, X., Fang, Y., Yan, O., Xu, H., Li, L., Li, W. & Huang, W. 2013. Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: A meta-analysis. Molecular Biology Reports 40(5): 3591-3596.

Farazi, A., Sofian, M., Jabbariasl, M. & Keshavarz, S. 2014. Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients. Tuberculosis Research and Treatment 2014. doi.org/10.1155/2014/412893.

Farrell, G.C. 1994. Drug-Induced Liver Disease. Edinburgh: Churchill Livingstone.

Hatin, W.I., Nur-Shafawati, A.R., Zahri, M.K., Xu, S., Jin, L., Tan, S.G., Rizman-Idid, M. & Zilfalil, B.A. 2011. Population genetic structure of peninsular Malaysia Malay sub-ethnic groups. PLoS ONE 6(4): e18312.

Huang, Y.S. 2014. Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury. Journal of the Chinese Medical Association 77(4): 169-173.

Huang, Y.S., Su, W.J., Huang, Y.H., Chen, C.Y., Chang, F.Y., Lin, H.C. & Lee, S.D. 2007. Genetic polymorphisms of manganese superoxide dismutase, NAD (P)H: Quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. Journal of Hepatology 47(1): 128-134.

Huang, Y.S., Chern, H.D., Su, W.J., Wu, J.C., Chang, S.C., Chiang, C.H., Chang, F.Y. & Lee, S.D. 2003. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37(4): 924-930.

Huang, Y.S., Chern, H.D., Su, W.J., Wu, J.C., Lai, S.L., Yang, S.Y., Chang, F.Y. & Lee, S.D. 2002. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35(4): 883-889.

Kim, S.H., Kim, S.H., Lee, J.H., Lee, B.H., Yoon, H.J., Shin, D.H., Park, S.S., Jang, S.B., Park, J.S. & Jee, Y.K. 2015. Superoxide dismutase gene (SOD1, SOD2, and SOD3) polymorphisms and antituberculosis drug-induced hepatitis. Allergy, Asthma & Immunology Research 7(1): 88-91.

Kurniawati, F., Sulaiman, S.A.S. & Gillani, S.W. 2012. Adverse drug reactions of primary anti-tuberculosis drugs among tuberculosis patients treated in chest clinic. International Journal of Pharmacy And Life Sciences 3(1): 1331-1338.

Lucena, M.I., Garcia-Martin, E., Andrade, R.J., Martinez, C., Stephens, C., Ruiz, J.D., Ulzurrun, E., Fernandez, M.C., Romero-Gomez, M., Castiella, A., Planas, R., Duran, J.A., De Dios, A.M., Guarner, C., Soriano, G., Borraz, Y. & Agundez, J.A. 2010. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology 52(1): 303-312.

Marzuki, O., Fauzi, A., Ayoub, S. & Kamarul Imran, M. 2008. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singapore Medical Journal 49(9): 688.

McDonagh, E.M., Boukouvala, S., Aklillu, E., Hein, D.W., Altman, R.B. & Klein, T.E. 2014. PharmGKB summary: Very important pharmacogene information for N-acetyltransferase 2.  Pharmacogenetics and Genomics 24(8): 409-425.

Ministry of Health Malaysia. 2015. Global Aids Response Progress Report Malaysia. http://www.unaids.org/sites/default/files/country/documents/MYS_narrative_report_2015.pdf. Accessed on 15 December 2018.

Ministry of Health Malaysia. 2018. Health Facts. http://www.moh.gov.my/resources/index/Penerbitan/Penerbitan%20Utama/Fakta%20kesihatan/KKM_HEALTH_FACTS_2018_new.pdf. Accessed 6th January 2019.

Nanashima, K., Mawatari, T., Tahara, N., Higuchi, N., Nakaura, A., Inamine, T., Kondo, S., Yanagihara, K., Fukushima, K., Suyama, N., Kohno, S. & Tsukamoto, K. 2012. Genetic variants in antioxidant pathway: Risk factors for hepatotoxicity in tuberculosis patients. Tuberculosis (Edinburgh, Scotland) 92(3): 253-259.

Nissapatorn, V., Lim, Y.A.L., Jamaiah, I., Man Chin, H., Ilyana, M., Nonaziah, M., Siti Hasifah, A. & Kuppusamy, I. 2007. Tuberculosis in Malaysia: A continuing surge. Southeast Asian Journal of Tropical Medicine and Public Health 38: 231.

Rafiza, S., Rampal, K.G. & Tahir, A. 2011. Prevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia. BMC Infectious Diseases 11: 19.

Ruhl, C.E. & Everhart, J.E. 2005. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clinical Gastroenterology and Hepatology 3(12): 1260-1268.

Saukkonen, J.J., Cohn, D.L., Jasmer, R.M., Schenker, S., Jereb, J.A., Nolan, C.M., Peloquin, C.A., Gordin, F.M., Nunes, D., Strader, D.B., Bernardo, J., Venkataramanan, R. & Sterling, T.R. 2006. An official ATS statement: Hepatotoxicity of antituberculosis therapy. American Journal of Respiratory and Critical Care Medicine 174(8): 935-952.

Shang, P., Xia, Y., Liu, F., Wang, X., Yuan, Y., Hu, D., Tu, D., Chen, Y., Deng, P. & Cheng, S. 2011. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS ONE 6(7): e21836.

Sun, F., Chen, Y., Xiang, Y. & Zhan, S. 2008. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: A meta-analysis. The International Journal of Tuberculosis and Lung Disease 12(9): 994-1002.

Teixeira, R.L., Morato, R.G., Cabello, P.H., Muniz, L.M., Moreira Ada, S., Kritski, A.L., Mello, F.C., Suffys, P.N., Miranda, A.B. & Santos, A.R. 2011. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Memorias do Instituto Oswaldo Cruz 106(6): 716-724.

Thongraung, W., Lertphongpiroon, W., Pungrassami, P. & Ratanajamit, C. 2012. Physicians' practices regarding management of antituberculosis drug-induced hepatotoxicity. Southeast Asian Journal of Tropical Medicine and Public Health 43(3): 724-734.

Tostmann, A., Boeree, M.J., Aarnoutse, R.E., de Lange, W.C., van der Ven, A.J. & Dekhuijzen, R. 2008. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. Journal of Gastroenterology and Hepatology 23(2): 192-202.

Vizirianakis, I.S. 2014. Handbook of Personalized Medicine: Advances in Nanotechnology, Drug Delivery, and Therapy. 1st ed. Boca Raton: CRC Press.

Wang, F.J., Wang, Y., Niu, T., Lu, W.X., Sandford, A. & He, J.Q. 2016. Update meta‐analysis of the CYP 2E1 RsaI/PstI and DraI polymorphisms and risk of antituberculosis drug‐induced hepatotoxicity: Evidence from 26 studies. Journal of Clinical Pharmacy and Therapeutics 41(3): 334-340.

Wattanapokayakit, S., Mushiroda, T., Yanai, H., Wichukchinda, N., Chuchottawon, C., Nedsuwan, S., Rojanawiwat, A., Denjanta, S., Kantima, T., Wongyai, J., Suwankesawong, W., Rungapiromnan, W., Kidkeukarun, R., Bamrungram, W., Chaiwong, A., Suvichapanich, S., Mahasirimongkol, S. & Tokunaga, K. 2016. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients. The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union against Tuberculosis and Lung Disease 20(10): 1364-1369.

World Health Organization. 2010. Guidelines for Treatment of Tuberculosis. 4th ed. http://www.who.int/tb/publications/2010/9789241547833/en/. Accessed on 13 August 2018.

Xue, H., Hou, Y. & Liu, H. 2002. The general investigation of the increased hepatotoxicity caused by isoniazid in combination with rifampin. Chinese Journal Modern Applied Pharmacy 19: 463-465.

Yuliwulandari, R., Susilowati, R.W., Wicaksono, B.D., Viyati, K., Prayuni, K., Razari, I., Kristin, E., Syafrizal, Subagyo, Sri Diana, E., Setiawati, S., Ariyani, A., Mahasirimongkol, S., Yanai, H., Mushiroda, T. & Tokunaga, K. 2016. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis. Journal of Human Genetics 61(6): 533-537.

Zerbino, D.R., Achuthan, P., Akanni, W., Amode, M.R., Barrell, D., Bhai, J., Billis, K., Cummins, C., Gall, A. & Girón, C.G. 2017. Ensembl 2018. (Ensembl Release 95). Nucleic Acids Research 46(D1): D754-D761.

*Pengarang untuk surat-menyurat; email: vishalasivapalan87@gmail.com